Suchergebnisse

Am Beispiel des Charismas der Sonja Ghandi, der ursprünglich aus Italien stammenden Schwiegertochter Indira Ghandis, arbeitet die Verfasserin die Rolle dreier für Indien typischer Charismaformen heraus. Zentral ist dabei das dynastische Erbcharisma, das mit dem "magischen" Namen der Familie Nehru/Gandhi verknüpft ist. Zweitens profitierte Sonja Ghandi mittelbar von dem Märtyrercharisma ihrer ermordeten Schwiegermutter Indira und ihres ermordeten Ehemannes Rajiv. Nicht minder wichtig ist jedoch drittes Sonjas persönliches "Charisma der Entsagung", das sie durch den Verzicht auf das Premierministeramt erlangte. Zeitversetzt war für ihre politische Karriere zunächst das dynastische Charisma entscheidend, später gewann das durch persönliche Entsagung erworbene Charisma an Bedeutung. (ICE2)

AbstractThe high prices of biotherapeutics remain an area of concern for various national and international agencies working toward developing strategies for monitoring, evaluating, and managing the prices of medicines to promote equitable access. This paper deploys a unique study design to identify emerging themes and determine the elements influencing the price of biotherapeutics specifically biosimilars. This review is based on a bibliometric and qualitative synthesis approach to generate a new line of thinking for future studies. The findings enable knowledge assimilation for policy decisions. The results indicate that while the factors like market share, market competition, and pricing policies are extensively explored by researchers, the factors such as innovation capability, product development costs, and local factors like regulatory ecosystem can be further examined as potential influencers of prices. Further, pricing frameworks and regulations designed for generic drugs cannot be replicated to estimate the prices of biotherapeutics. As a result, policymakers must take the necessary actions to construct innovative pricing frameworks for this class of products that are in conformity with national policies, regulations, market dynamics, and economics. Moreover, studies on incentives and profit margins associated with the last‐mile delivery and accessibility of high‐cost biotherapeutics are essential for their efficient adoption.